BMY - Bristol-Myers Squibb Company
After hours:
| Previous close | 63.71 |
| Open | 63.69 |
| Bid | 0.00 x 1100 |
| Ask | 0.00 x 800 |
| Day's range | 63.15 - 64.60 |
| 52-week range | 63.07 - 81.44 |
| Volume | |
| Avg. volume | 8,125,349 |
| Market cap | 135.379B |
| Beta (5Y monthly) | 0.43 |
| PE ratio (TTM) | 18.79 |
| EPS (TTM) | 3.43 |
| Earnings date | 27 July 2023 |
| Forward dividend & yield | 2.28 (3.58%) |
| Ex-dividend date | 06 Apr 2023 |
| 1y target est | 79.70 |
ZacksBristol Myers' (BMY) Lung Cancer Drug NDA Gets Priority Review
Bristol Myers' (BMY) NDA for repotrectinib for treating patients with NSCLC receives Priority Review from the FDA.
Motley FoolIs Bristol Myers Squibb a Top Dividend Stock?
Its hefty yield isn't the only reason to consider buying this top pharma stock.
Business WireBristol Myers Squibb to Hold R&D Day on September 14
NEW YORK, May 31, 2023--Bristol Myers Squibb to Hold R&D Day on September 14
Business WireBristol Myers Squibb to Present Late-Breaking Data for Breyanzi (lisocabtagene maraleucel) in Relapsed or Refractory Follicular Lymphoma and Mantle Cell Lymphoma at 2023 International Conference on Malignant Lymphoma
PRINCETON, N.J., May 30, 2023--BMS to Present Late-Breaking Data for Breyanzi in Relapsed or Refractory Follicular Lymphoma and Mantle Cell Lymphoma at 2023 ICML
Business WireU.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Repotrectinib for the Treatment of Patients with Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer
PRINCETON, N.J., May 30, 2023--US FDA Accepts for Priority Review BMS's Application for Repotrectinib
ZacksFDA Accepts Iovance's (IOVA) BLA Filing for Melanoma Drug
The FDA grants priority review to Iovance's (IOVA) filing seeking approval for its lead pipeline candidate in melanoma indication. A decision is expected before November-end.
Simply Wall St.We Think Bristol-Myers Squibb (NYSE:BMY) Can Stay On Top Of Its Debt
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
ZacksBristol Myers (BMY) Thrombosis Drug Gets Fast Track Designation
Bristol Myers (BMY) obtains Fast Track Designation from the FDA for milvexian, which is being developed in collaboration with Johnson and Johnson's Janssen.
Business WireBristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) with Chemotherapy as Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer at High Risk of Recurrence in Patients with Tumor Cell PD-L1 Expre...
PRINCETON, N.J., May 26, 2023--BMS Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) with Chemotherapy as Neoadjuvant Treatment of Resectable...
Business WireBristol Myers Squibb’s Breyanzi (lisocabtagene maraleucel) is First and Only CAR T to Deliver Deep and Durable Efficacy in Pivotal Multicenter Trial in Relapsed or Refractory Chronic Lymphocytic Leukemia, Based on Data Presented at ASCO 2023
PRINCETON, N.J., May 25, 2023--BMS's Breyanzi is First and Only CAR T to Deliver Deep and Durable Efficacy in Pivotal Multicenter Trial in Relapsed or Refractory Chronic....
Business WireBristol Myers Squibb to Present First Results at ASCO and EHA from Phase 3 COMMANDS Study of Reblozyl® (luspatercept-aamt) in First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS)
PRINCETON, N.J., May 25, 2023--BMS to Present First Results at ASCO & EHA from Phase 3 COMMANDS Study of Reblozyl in First-Line Treatment...
ZacksMirati's (MRTX) Sitravatinib Fails Lung Cancer Study, Stock Down 8%
Mirati Therapeutics' (MRTX) phase III study evaluating sitravatinib as a combination therapy in certain NSCLC patients fails to meet its primary endpoint.
Business WireMilvexian Granted U.S. FDA Fast Track Designation for All Three Indications Under Evaluation in Phase 3 Librexia Program: Ischemic Stroke, Acute Coronary Syndrome and Atrial Fibrillation
PRINCETON, N.J., May 25, 2023--Milvexian Granted U.S. FDA Fast Track Designation for All Three Indications Under Evaluation in Phase 3 Librexia Program
- Zacks
Bristol Myers (BMY) Reports Pulmonary Fibrosis Study Results
Bristol Myers' (BMY) idiopathic pulmonary fibrosis drug reduces the rate of lung function decline in a phase II study.
Business WireBristol Myers Squibb’s Investigational LPA1 Antagonist Reduces the Rate of Lung Function Decline in Patients with Idiopathic Pulmonary Fibrosis
PRINCETON, N.J., May 22, 2023--Bristol Myers Squibb’s Investigational LPA1 Antagonist Reduces the Rate of Lung Function Decline in Patients with Idiopathic Pulmonary Fibrosis
- Simply Wall St.
Bristol-Myers Squibb (NYSE:BMY) sheds 3.3% this week, as yearly returns fall more in line with earnings growth
When you buy and hold a stock for the long term, you definitely want it to provide a positive return. Furthermore...
Motley Fool1 Dirt Cheap Dividend Stock to Buy in May
Let's consider the case of Bristol Myers Squibb (NYSE: BMY). The best pharmaceutical companies generally have deep pipelines that allow them to launch new products regularly and keep their revenue and earnings flowing in the right direction over the long run. This description applies to Bristol Myers Squibb.
- Simply Wall St.
A Closer Look At Bristol-Myers Squibb Company's (NYSE:BMY) Impressive ROE
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...
Motley FoolIs Bristol-Myers Squibb Stock a Buy Now?
Bristol-Myers Squibb (NYSE: BMY) is a top healthcare company with a rich history that goes back to the 1800s. Share prices of Bristol-Myers are down 11% over the past year, while the S&P 500 has been flat. A key reason investors haven't been too excited about Bristol-Myers' business is that the company's growth rate has typically been modest.
Motley Fool3 High-Yielding Dividend Stocks That Could Pay You Forever
There has been no shortage of companies cutting dividends in the past year. If you're looking for some safety on the dividend front, consider Bristol Myers Squibb (NYSE: BMY), Verizon Communications (NYSE: VZ), and Coca-Cola (NYSE: KO).
- Simply Wall St.
Bristol-Myers Squibb Insiders Sell US$38m Of Stock, Possibly Signalling Caution \
In the last year, many Bristol-Myers Squibb Company ( NYSE:BMY ) insiders sold a substantial stake in the company which...
Motley Fool3 Things About Bristol-Myers Squibb That Smart Investors Know
When it comes to large and fairly complicated companies such as Bristol-Myers Squibb, (NYSE: BMY), the most knowledgeable investors tend to see a lot of things that casual observers miss. With that perspective in hand, let's explore three less-than-obvious things about Bristol-Myers that smart investors probably know, so that you'll have the benefit of their observations. Smart investors appreciate that Bristol-Myers isn't going to be expanding very much in the near term as a result of one of its big-earning medicines losing its exclusivity protections.
ZacksPharma ETFs Gain Post Q1 Earnings
Many industry bigwigs reported solid results, with some beating on earnings or revenues or both. As such, pharma ETFs have been in the green over the past month.
ZacksProthena (PRTA) Q1 Earnings and Revenues Miss Estimates
Prothena (PRTA) reports a wider loss in the first quarter. The company makes considerable pipeline progress.
Motley FoolWhich Is the Better Passive Income Stock, Eli Lilly or Bristol Myers Squibb?
Most pharma investors are familiar with power players like Eli Lilly (NYSE: LLY) and Bristol Myers Squibb, (NYSE: BMY) and both businesses have a lot to offer passive income investors too. As one of the world's most preeminent pharma conglomerates, Eli Lilly and its portfolio of products covers all sorts of illnesses, including Alzheimer's disease, diabetes, and different cancers. It also has 21 programs in phase 3 clinical trials, and another 21 in phase 2 trials.